Kolexia
Sevin Emmanuel
Oncologie médicale
Cabinet libéral
Caen, France
93 Activités
136 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs de la prostate Néphrocarcinome Tumeurs du rein Tumeurs de l'ovaire Tumeurs prostatiques résistantes à la castration Métastase tumorale Tumeurs de la trompe de Fallope Fatigue

Industries

Ipsen
13 collaboration(s)
Dernière en 2023
AstraZeneca
9 collaboration(s)
Dernière en 2023
MSD
7 collaboration(s)
Dernière en 2023
Lilly
3 collaboration(s)
Dernière en 2023

Dernières activités

QISEIN: Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast Cancer - Randomized, Placebo-controlled, Double-blind Study
Essai Clinique (Centre François-Baclesse)   10 novembre 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Supervised Physical Activity Quickly Improves Social Dimension of Quality of Life in Breast Cancer Patients.
Medicine and science in sports and exercise   26 juillet 2022
CABASTY: Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 65years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Essai Clinique (Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie)   09 mai 2022
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer: Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP
Essai Clinique (Unicancer)   18 février 2021
OPTINECK: Evaluation of Optimised Early Management in the Context of Radiochemotherapy for Curatively Treated Squamous Cell Carcinoma of the Head and Neck
Essai Clinique (Centre Henri-Becquerel)   26 août 2020
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
JAMA oncology   10 février 2020
Nonionotropic Action of Endothelial NMDA Receptors on Blood-Brain Barrier Permeability via Rho/ROCK-Mediated Phosphorylation of Myosin.
The Journal of neuroscience : the official journal of the Society for Neuroscience   17 janvier 2020